NASDAQ:ARWR Arrowhead Pharmaceuticals Q4 2026 Earnings Date & Estimates $61.65 +2.12 (+3.56%) Closing price 11/4/2026 04:00 PM EasternExtended Trading$60.86 -0.79 (-1.27%) As of 04:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Arrowhead Pharmaceuticals is estimated to report Q4 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ4 2026Announcement DateNovember 12, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Arrowhead Pharmaceuticals in Q4 2026Arrowhead Pharmaceuticals is expected to post earnings of -$1.52 per share on revenue of $61.18 million. Arrowhead Pharmaceuticals last reported on August 4, 2026, posting -$1.36 per share and missing the -$1.23 consensus estimate. Arrowhead Pharmaceuticals has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$1.52Expected Revenue$61.18 millionRecent Track RecordLast ReportedQ3 2026Last Quarter EPS-$1.36 (Missed by -$0.13)Last Quarter Revenue$75.25 millionEPS Beat Rate2 of last 8 quartersPrepare for the Q4 2026 CallEarnings HistoryCompany ProfileQ3 2026 Earnings ReportQ2 2026 Earnings ReportQ1 2026 Earnings Report Arrowhead Pharmaceuticals Q4 2026 Earnings FAQ When does Arrowhead Pharmaceuticals report Q4 2026 earnings? Arrowhead Pharmaceuticals (NASDAQ:ARWR) is estimated to report Q4 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Arrowhead Pharmaceuticals' Q4 2026 earnings call? Arrowhead Pharmaceuticals' Q4 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Arrowhead Pharmaceuticals? Analysts expect Arrowhead Pharmaceuticals to post earnings of -$1.52 per share for Q4 2026. How much revenue is Arrowhead Pharmaceuticals expected to report? The consensus revenue estimate for Arrowhead Pharmaceuticals is $61.18 million for Q4 2026. Arrowhead Pharmaceuticals Earnings HeadlinesArrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending MaturityNovember 4 at 8:00 AM | businesswire.comArrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026November 2 at 8:00 AM | businesswire.com$250,000/Month- How You Can Learn from President TrumpPresident Trump has reportedly collected up to $250,000 a month from a single fund. Now investors can get access to the same fund for less than $20.November 5 at 1:00 AM | The Oxford Club (Ad)Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce TriglyceridesOctober 27, 2026 | businesswire.comArrowhead Pharmaceuticals And 2 Biotech Stocks To OwnOctober 24, 2026 | finance.yahoo.comArrowhead Pharmaceuticals (ARWR) Gets a Buy from Piper SandlerOctober 17, 2026 | theglobeandmail.comSee More Arrowhead Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arrowhead Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arrowhead Pharmaceuticals and other key companies, straight to your email. Email Address About Arrowhead PharmaceuticalsArrowhead Pharmaceuticals (NASDAQ:ARWR) is a biopharmaceutical company focused on developing medicines that silence disease-causing genes using RNA interference (RNAi). The company’s proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi-based therapies to specific tissues and reduce the production of targeted proteins. Arrowhead’s research and development programs address a range of conditions, including cardiometabolic, pulmonary, liver, and central nervous system diseases. Its pipeline has included investigational therapies designed to treat disorders such as hypertriglyceridemia, liver disease, respiratory illness, and other conditions. The company’s products remain primarily in clinical development, and its programs have included collaborations and licensing arrangements with larger pharmaceutical companies. Founded in 2003, Arrowhead Pharmaceuticals is headquartered in Pasadena, California. Christopher Anzalone, Ph.D., serves as the company’s president and chief executive officer. Arrowhead’s operations are primarily focused on research, clinical development, and partnerships intended to advance RNAi medicines for patients in the United States and international markets.View Arrowhead Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushBloom Energy: The Off-Grid Answer to AI's Power DrainWhy ExxonMobil and Chevron Reminded Investors to Keep it SimpleEnergy Transfer's Earnings Miss May Be Hiding Its Strongest Advantage Upcoming Earnings Enbridge (11/6/2026)Brookfield Asset Management (11/6/2026)Humana (11/6/2026)Moderna (11/6/2026)Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
